View options
Result details

Results per page
Articles per page View Sort by

2 results matched your search query
Keywords = Schizophre

  • Open Access Research Article
    Export citation: APA   BibTeX   EndNote   RIS  
    Trends Journal of Sciences Research 2018, 3(3), 104-115. http://doi.org/10.31586/PharmaceuticalHealth.0303.01
    28 Views 17 Downloads PDF Full-text (858.621 KB)  HTML Full-text
    Abstract
    Objective: To examine which medication could lead to a higher short and long term smoking abstinence in patients with schizophrenia.Methods: A retrospective cohort study was conducted using General Electric (GE) medical records database (1995 ? 2011). The cohort consisted of adult smokers with diagnosis of schizophrenia newly initiating cessation medication.
    [...] Read more.
    Objective: To examine which medication could lead to a higher short and long term smoking abstinence in patients with schizophrenia.Methods: A retrospective cohort study was conducted using General Electric (GE) medical records database (1995 ? 2011). The cohort consisted of adult smokers with diagnosis of schizophrenia newly initiating cessation medication. Short term and long term outcomes of cessation were measured at 3 weeks and 1 year. Descriptive and chi-square analyses were used to determine the frequencies and associations of patient characteristics with the abstinence outcomes. Logistic regression models were carried out to determine the predictors of short term and long term abstinence. Results: The cohort consisted of 3,976 patients. Abstinence rate was highest for Varenicline, followed by Bupropion, NRT, and lastly combination at week 12. At one year, abstinence rate was highest for Varenicline, followed by combination, NRT, and lastly Bupropion. Age, race, household locations and receiving counseling were associated with abstinence. No significant differences were found between cessation medications. Conclusions: There were no statistically significant differences in quitting with type of cessation medication. Predictors of better abstinence identified included older age, white race, western household location. These factors should be considered when designing future interventions for schizophrenic population as this minority population may need more tailored approaches to achieve a successful cessation outcome.  Full article
    Figures

    Figure 1 of 1

    References
    [1]
    Evins, A.E., et al., A 12-week double-blind, placebo-controlled study of bupropion SR added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. Journal of clinical psychopharmacology, 2007. 27(4): p. 380.
    [2]
    Ferchiou, A., et al., Exploring the relationships between tobacco smoking and schizophrenia in first-degree relatives. Psychiatry research, 2012.
    [3]
    George, T.P., et al., A placebo-controlled trial of bupropion combined with nicotine patch for smoking cessation in schizophrenia. Biological psychiatry, 2008. 63(11): p. 1092-1096.
    [4]
    Lo, S., et al., Tobacco craving in smokers with and without schizophrenia. Schizophrenia research, 2011. 127(1-3): p. 241-245.
    [5]
    Leonard, S., S. Mexal, and R. Freedman, Smoking, genetics and schizophrenia: evidence for self medication. Journal of dual diagnosis, 2007. 3(3-4): p. 43.
    [6]
    Tsoi, D.T., M. Porwal, and A.C. Webster, Efficacy and safety of bupropion for smoking cessation and reduction in schizophrenia: systematic review and meta-analysis. The British Journal of Psychiatry, 2010. 196(5): p. 346-353.
    [7]
    Cather, C., et al., Achieving Smoking Cessation in Individuals with Schizophrenia: Special Considerations. CNS Drugs, 2017. 31(6): p. 471-481.
    [8]
    Pierce, J.P. and E.A. Gilpin, Impact of over-the-counter sales on effectiveness of pharmaceutical aids for smoking cessation. JAMA: the journal of the American Medical Association, 2002. 288(10): p. 1260-1264.
    [9]
    Jimenez-Ruiz, C., I. Berlin, and T. Hering, Varenicline: a novel pharmacotherapy for smoking cessation. Drugs, 2009. 69(10): p. 1319-1338.
    [10]
    Fava, M., et al., 15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. Primary care companion to the Journal of clinical psychiatry, 2005. 7(3): p. 106.
    [11]
    Chou, K.-R., et al., The effectiveness of nicotine-patch therapy for smoking cessation in patients with schizophrenia. International journal of nursing studies, 2004. 41(3): p. 321-330.
    [12]
    Chen, H.-K., T.-H. Lan, and B.-J. Wu, A double-blind randomized clinical trial of different doses of transdermal nicotine patch for smoking reduction and cessation in long-term hospitalized schizophrenic patients. European archives of psychiatry and clinical neuroscience, 2013. 263(1): p. 75-82.
    [13]
    Evins, A.E., et al., A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia. Nicotine & tobacco research, 2001. 3(4): p. 397-403.
    [14]
    Evins, A.E., et al., A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia. Journal of clinical psychopharmacology, 2005. 25(3): p. 218.
    [15]
    George, T.P., et al., A placebo controlled trial of bupropion for smoking cessation in schizophrenia. Biological psychiatry, 2002. 52(1): p. 53-61.
    [16]
    Bloch, B., et al., Preliminary effects of bupropion and the promoter region (HTTLPR) serotonin transporter (SLC6A4) polymorphism on smoking behavior in schizophrenia. Psychiatry research, 2010. 175(1): p. 38-42.
    [17]
    Weiner, E., et al., Varenicline for smoking cessation in people with schizophrenia: a double blind randomized pilot study. Schizophrenia research, 2011. 129(1): p. 94-95.
    [18]
    Williams, J.M., et al., A randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder. The Journal of clinical psychiatry, 2012. 73(5): p. 654-660.
    [19]
    Evins, A.E., et al., Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial. Jama, 2014. 311(2): p. 145-54.
    [20]
    Zammit, S., et al., A longitudinal study of premorbid IQ score and risk of developing schizophrenia, bipolar disorder, severe depression, and other nonaffective psychoses. Archives of general psychiatry, 2004. 61(4): p. 354.
    [21]
    Fiore, M., Treating tobacco use and dependence: 2008 update: Clinical practice guideline. 2008: DIANE Publishing.
    [22]
    Audrain-McGovern, J. and N.L. Benowitz, Cigarette smoking, nicotine, and body weight. Clin Pharmacol Ther, 2011. 90(1): p. 164-8.
    [23]
    Cokkinides, V.E., et al., Racial and ethnic disparities in smoking-cessation interventions: analysis of the 2005 National Health Interview Survey. American journal of preventive medicine, 2008. 34(5): p. 404-412.
    [24]
    Health, U.S.D.o. and S. Human, Agency for healthcare research and quality. Center for Financing, Access and Cost Trends, 2006.
    [25]
    Centers for Disease, C. and Prevention, State medicaid coverage for tobacco-dependence treatments---United States, 2009. MMWR. Morbidity and mortality weekly report, 2010. 59(41): p. 1340.
    [26]
    Ferketich, A.K., Y. Khan, and M.E. Wewers, Are physicians asking about tobacco use and assisting with cessation? Results from the 2001?2004 national ambulatory medical care survey (NAMCS). Preventive medicine, 2006. 43(6): p. 472-476.
    [27]
    Schnoll, R.A., et al., Smoking cessation treatment by primary care physicians: an update and call for training. American journal of preventive medicine, 2006. 31(3): p. 233-239.
    [28]
    Tsoi, D.T., M. Porwal, and A.C. Webster, Interventions for smoking cessation and reduction in individuals with schizophrenia. Cochrane Database Syst Rev, 2013(2): p. Cd007253.
    [29]
    Kishi, T. and N. Iwata, Varenicline for smoking cessation in people with schizophrenia: systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci, 2015. 265(3): p. 259-68.
    [30]
    T?nnesen, P., et al., A multicentre, randomized, double?blind, placebo?controlled, 1?year study of bupropion SR for smoking cessation. Journal of internal medicine, 2003. 254(2): p. 184-192.
    [31]
    Fossati, R., et al., A double-blind, placebo-controlled, randomized trial of bupropion for smoking cessation in primary care. Archives of internal medicine, 2007. 167(16): p. 1791-1797.
    [32]
    Gariti, P., et al., Detecting smoking following smoking cessation treatment. Drug and alcohol dependence, 2002. 65(2): p. 191-196.
    [33]
    Williams, K.E., et al., A double-blind study evaluating the long-term safety of varenicline for smoking cessation*. Current Medical Research and Opinion?, 2007. 23(4): p. 793-801.
    [34]
    Stead, L.F. and T. Lancaster, Combined pharmacotherapy and behavioural interventions for smoking cessation. Cochrane Database Syst Rev, 2012. 10(10).
    [35]
    Alamar, B. and S.A. Glantz, Effect of increased social unacceptability of cigarette smoking on reduction in cigarette consumption. American Journal of Public Health, 2006. 96(8): p. 1359.
    [36]
    Lee, C.-w. and J. Kahende, Factors associated with successful smoking cessation in the United States, 2000. American Journal of Public Health, 2007. 97(8).
    [37]
    Tonstad, S., et al., Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. Jama, 2006. 296(1): p. 64-71.
    [38]
    Hurt, R.D., et al., Bupropion for pharmacologic relapse prevention to smoking: predictors of outcome. Addict Behav, 2002. 27(4): p. 493-507.
    [39]
    Vermeire, E., et al., Patient adherence to treatment: three decades of research. A comprehensive review. Journal of clinical pharmacy and therapeutics, 2001. 26(5): p. 331-342.
    [40]
    Crawford, A.G., et al., Comparison of GE Centricity Electronic Medical Record database and National Ambulatory Medical Care Survey findings on the prevalence of major conditions in the United States. Population health management, 2010. 13(3): p. 139-150.
  • Open Access Research Article
    Export citation: APA   BibTeX   EndNote   RIS  
    Trends Journal of Sciences Research 2018, 3(3), 133-137. http://doi.org/10.31586/Psychiatry.0303.05
    36 Views 8 Downloads PDF Full-text (686.826 KB)  HTML Full-text
    Abstract
    Objective: Suicide is the most common cause of premature death of schizophrenia. This study investigated the relationship between cholesterol levels and suicidal behaviour in chronic psychosis. Methods: The study group consisted of 109 schizophrenia, schizoaffective and other non affectice psychosis defined by Diagnostic and Statistical Manual of Mental Disorders, 5th
    [...] Read more.
    Objective: Suicide is the most common cause of premature death of schizophrenia. This study investigated the relationship between cholesterol levels and suicidal behaviour in chronic psychosis. Methods: The study group consisted of 109 schizophrenia, schizoaffective and other non affectice psychosis defined by Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-V) criteria. Lifetime suicide attempts of patients were retrospectively screened. The patients were divided into two groups with and without suicide. Serum cholesterol levels were compared between two groups. Results: The mean total cholesterol, triglyceride, HDL and LDL levels were 163.8 mg/dl,150.8 mg/dl,40.8 mg/dl and 132.4 mg/dl, respectively in the study group while they were 197.1 mg/dl, 194 mg/dl, 44.9 mg/dl and 124.2 mg/dl, respectively in the control group. Total cholesterol levels were significantly lower than patients with suicidal attempts compared with the patients with no suicidal attemps (p=0,03). No association was found between suicidal attempt and HDL cholesterol (p=0,24), triglyceride (p=0,193), and LDL(p=0,45). Conclusion: This result supports the hypothesis of association low plasma cholesterol levels and suicidal behavior in psychosis  Full article
    References
    [1]
    Palmer BA, Pankratz VS, Bostwick JM. The life time risk of suicide in schizophrenia: a reexamination. Arch Gen Psychiatry. 2005; 62:247-253
    [2]
    Shrivastava A, Shah N, Johnston M, Stitt L, Thakar M. Predictors of long-termoutcome of first-episode schizophrenia: A ten-year follow-up study. Indian J Psychiatry. 2010; 52:320?326
    [3]
    Barak Y, Baruch Y, Achiron A, Aizenberg D. Suicide attempts of schizophrenia patients: a case-controlled study in tertiary care. J PsychiatrRes. 2008; 42:822-826.
    [4]
    Pompili M, Serafini G, Innamorati M, Lester D, Shrivastava A, Girardi P, Nordentoft M. Suicide risk in first episode psychosis: A selective review of the current literature. Schizophr Res. 2011;129:1?11.
    [5]
    Goldacre M, Seagroatt V, Hawton K. Suicide after discharge from psychiatric inpatient care. Lancet. 1993;342:283?6
    [6]
    Ainiyet B, Rybakowski JK. Suicidal behavior in schizophrenia may be related to low lipid levels. Med Sci Monit. 2014;20:1486?1490
    [7]
    Kim YK, Lee HJ, Kim JY, Yoon DK, Choi SH, Lee MS. Low serum cholesterol is correlated to suicidality in a Korean sample. Acta Psychiatr Scand. 2002;105:141?148.
    [8]
    Ernst C, Mechawar N, Turecki G. Suicide neurobiology. Prog Neurobiol. 2009;89:315?333
    [9]
    Lalovic A, Levy E, Luheshi G, Canetti L, Grenier E, Sequeira A, Turecki G. Cholesterol content in brains of suicide completers. Int J Neuropsychopharmacol. 2007;10:159?166
    [10]
    Uzun O, Tamam L, Ozculer T, Doruk A, Unal. Specific characteristics of suicide attempts in patients with schizophrenia in Turkey. Isr J Psychiatry Relat Sci. 2009;46:189-194.
    [11]
    Atmaca M, Kuloglu M, Tezcan E, Ustundag B. Serum leptin and cholesterol levels in schizophrenic patients with and without suicide attempts. Acta Psychiatr Scand. 2003;108:208?214.
    [12]
    Marcinko D, Martinac M, Karlovi? D, Loncar C. Cholesterol serum levels in violent and non-violent young male schizophrenic suicide attempters. Psychiatr Danub. 2004;16:161?164.
    [13]
    Marcinko D, Martinac M, KarloviC D, Filipci? I, Loncar C, Pivac N, Jakovljevi? M. Are there differences in serum cholesterol and cortisol concentrations between violent and non violent schizophrenic male suicide attempters? CollAntropol. 2005;29:153?157.
    [14]
    Tarrier N, Khan S, Cater J, Picken A. The subjective consequences of suffering a firs tepisode psychosis: Trauma and suicide behaviour. Soc Psychiatry Psychiatr Epidemiol. 2007;42:29?35
    [15]
    Shrivastava A, Johnston M, Campbell R, Sousa AD, Shah N. Serum cholesterol and Suicide in first episode psychosis: A preliminary Study. Indian J Psychiatry. 2017; 59: 478?482.
    [16]
    Lester D. Serum cholesterol levels and suicide: A meta-analysis. Suicide Life Threat Behav. 2002;32:333?46
    [17]
    Freemantle E, Chen GG, Cruceanu C, Mechawar N, Turecki G. Analysis of oxysterols and cholesterol in prefrontal cortex of suicides. Int J Neuro-psychopharmacol. 2013;16:1241?1244
    [18]
    Papakostas GI, Petersen T, Mischoulon D, Hughes ME, Alpert JE, Nierenberg AA, Rosenbaum JF, Fava M. Serum cholesterol and serotonergic function in maj?r depressive disorder. PsychiatryRes. 2003;9:137?145
Filter options
Publication Date
From to
Refine Publication Date
Subject Areas
Refine Subjects
Article Types
Refine Article Types
Countries / Territories
Refine Countries / Territories